Cell & Gene Therapy Bioanalytical Testing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Oncology is the fastest growing sector, North America is the largest market

The Global Cell & Gene Therapy Bioanalytical Testing Services Market is projected to grow significantly from USD 567.27 Million in 2025 to USD 961.36 Million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.19%. These services involve specialized scientific assessments critical for validating the potency, safety, and viral vector characteristics of therapeutic products throughout their development cycle. The market's expansion is primarily driven by the rapid increase in therapeutic candidates entering clinical phases and the escalating demand for stringent safety data mandated by health authorities, thereby necessitating thorough third-party validation to mitigate risks. In the first half of 2025, there were 1,905 ongoing clinical trials globally, according to the Alliance for Regenerative Medicine and the American Society of Gene & Cell Therapy.

Market Drivers

The swift growth of the cell and gene therapy research and development pipeline serves as a fundamental driver, propelling the bioanalytical testing services market by creating immense demand for validation capacity. As novel therapeutic modalities proliferate, developers increasingly rely on specialized partners for critical safety and potency assays that can keep pace with clinical timelines. By March 2025, the global development pipeline encompassed over 4,000 therapies across all stages, as reported by the American Society of Gene & Cell Therapy, ensuring a sustained need for rigorous bioanalytical testing, including immunogenicity and viral vector characterization for every new candidate.

Furthermore, substantial growth in capital investments for advanced therapy development provides the financial resources required for premium outsourced bioanalysis, thereby accelerating market demand. This influx of capital from pharmaceutical entities directly correlates with increased spending on testing services to ensure regulatory compliance, exemplified by transactions like Roche’s acquisition of Poseida Therapeutics for approximately $1.5 billion and Novartis’s acquisition of Kate Therapeutics for $1.1 billion, as reported by CGTLive in March 2025. These high-value investments underscore the industry’s commitment to advancing complex therapies, directly funding the essential testing workflows for commercialization.

Market Challenges

A significant impediment to the growth of the Global Cell & Gene Therapy Bioanalytical Testing Services Market is the severe shortage of highly specialized personnel. Given that these advanced therapies depend on intricate biological assays for validation, the industry requires a workforce with specific scientific expertise that is currently in limited supply. This scarcity leads to substantial operational bottlenecks, as testing service providers struggle to recruit and retain qualified staff necessary for executing complex validation studies within tight regulatory timelines.

Consequently, the inability to scale workforce capacity restricts the volume of projects service providers can undertake, resulting in extended lead times and delays in client product development lifecycles. This labor supply-demand imbalance is further intensified by the rapid expansion of the commercial landscape, which, according to the Alliance for Regenerative Medicine, saw the global sector grow to almost 3,000 therapeutic developers in 2025. This high density of developers intensely competes for the same finite group of bioanalytical experts, exacerbating attrition rates and impeding testing firms from maintaining the stable, expert teams required to meet the surging demand for safety and potency testing.

Market Trends

The bioanalytical market is being reshaped by two key trends: the Expansion of Specialized Viral Vector Characterization Capabilities and a Shift Towards End-to-End Integrated Bioanalytical Service Models. As adeno-associated virus (AAV) vectors become the preferred method for gene delivery, testing services are increasingly concentrating on advanced assays to determine crucial quality attributes such as capsid titer and full-to-empty ratios. This technical specialization is directly driven by the surging clinical adoption of these specific vectors, which necessitates rigorous validation distinct from broader therapeutic testing.

According to PackGene in September 2025, an analysis identified 343 active AAV trials, marking a significant 34% increase in development activity for this vector class compared to 2022 benchmarks. Concurrently, the industry is seeing a definitive Shift Towards End-to-End Integrated Bioanalytical Service Models, spurred by the sector's maturation from experimental research to commercial-scale manufacturing.

Service providers are consolidating workflows to offer comprehensive lifecycle management - from early biomarker discovery to post-market surveillance - to support high-value commercial assets. This integration is essential as the market increasingly focuses on a select group of approved, high-revenue therapies that demand consistent, large-scale testing capacity rather than fragmented, project-based analysis. As of January 2025, the Alliance for Regenerative Medicine reported that 75% of the global sector's revenue is generated by fewer than 10 commercial products, highlighting the critical need for robust, integrated testing platforms capable of supporting these blockbuster therapies.

Key Market Players

• BioAgilytix Labs Inc.
• KCAS Bio
• IQVIA, Inc.
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Prolytix pvt ltd
• Pharmaron Biologics (UK) Ltd
• Charles River Laboratories International, Inc.
• Syneos Health Ltd
• Intertek Group Plc

Report Scope

In this report, the Global Cell & Gene Therapy Bioanalytical Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy Bioanalytical Testing Services Market, by Test Type:

• Bioavailability & Bioequivalence Studies
• Pharmacokinetics
• Pharmacodynamics
• Other test Stage of Development

Cell & Gene Therapy Bioanalytical Testing Services Market, by Product Type:

• Gene Therapy
• Gene-Modified Cell Therapy
• Cell Therapy

Cell & Gene Therapy Bioanalytical Testing Services Market, by Stage of Development:

• Non-Clinical
• Clinical

Cell & Gene Therapy Bioanalytical Testing Services Market, by Indication:

• Oncology
• Infectious Diseases
• Neurological disorders
• Rare Diseases
• Others

Cell & Gene Therapy Bioanalytical Testing Services Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Bioanalytical Testing Services Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.